QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)

Aptose Biosciences - APTO Stock Forecast, Price & News

$0.71
-0.01 (-1.39%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.69
$0.73
50-Day Range
$0.46
$0.76
52-Week Range
$0.45
$2.14
Volume
166,543 shs
Average Volume
338,782 shs
Market Capitalization
$65.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75

Aptose Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
990.9% Upside
$7.75 Price Target
Short Interest
Healthy
0.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.52mentions of Aptose Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$6,800 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.46) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

333rd out of 1,022 stocks

Biological Products, Except Diagnostic Industry

53rd out of 171 stocks

APTO stock logo

About Aptose Biosciences (NASDAQ:APTO) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Stock News Headlines

H.C. Wainwright Reaffirms Their Buy Rating on Aptose Biosciences (APTO)
Aptose Reports Results for the Third Quarter 2022
Aptose Biosciences Inc. (APTO)
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
Aptose Biosciences Inc
Aptose Reports Results for the Second Quarter 2022
Aptose names new CFO
See More Headlines
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Company Calendar

Last Earnings
11/11/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/28/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTO
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+990.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-65,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.81 per share

Miscellaneous

Free Float
82,198,000
Market Cap
$65.57 million
Optionable
Optionable
Beta
1.46

Key Executives

  • Dr. William G. Rice Ph.D. (Age 59)
    Chairman, Pres & CEO
  • Mr. Gregory K. Chow CPA (Age 45)
    MBA, BA, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Ernest Kitt B.S.
    M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell (Age 73)
    Chief Medical Officer
  • Mr. Peter Murray
    Director of Clinical Devel.













APTO Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares.
View APTO analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price forecast for 2023?

4 analysts have issued 1-year price targets for Aptose Biosciences' stock. Their APTO share price forecasts range from $5.00 to $12.00. On average, they predict the company's stock price to reach $7.75 in the next twelve months. This suggests a possible upside of 986.3% from the stock's current price.
View analysts price targets for APTO
or view top-rated stocks among Wall Street analysts.

How have APTO shares performed in 2022?

Aptose Biosciences' stock was trading at $1.35 at the beginning of the year. Since then, APTO stock has decreased by 47.2% and is now trading at $0.7134.
View the best growth stocks for 2022 here
.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 692,100 shares, an increase of 163.7% from the October 31st total of 262,500 shares. Based on an average daily volume of 356,000 shares, the short-interest ratio is presently 1.9 days.
View Aptose Biosciences' Short Interest
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our APTO earnings forecast
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, November, 11th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same period in the previous year, the company earned ($0.15) EPS.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (7.46%), Carlson Capital L P (2.18%), Sigma Planning Corp (0.97%), Annandale Capital LLC (0.77%), Sanders Morris Harris LLC (0.71%) and Voss Capital LLC (0.65%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Gregory K Chow, Jotin Marango, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends
.

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $0.71.

How much money does Aptose Biosciences make?

Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $65.84 million. The biotechnology company earns $-65,350,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.

This page (NASDAQ:APTO) was last updated on 12/8/2022 by MarketBeat.com Staff